Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

By RSS

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

GLG News by Cymbalta Prescribers for Neuropathic Pain (US)

Articles with lock require a subscription to GLG News |

Request a free trial

July 7, 2008

Complicated issue
Analysis of: Doctors Say Medication Is Overused in Dementia | www.nytimes.com
Author: GLG Expert Contributor

Many times, nursing homes will call doctors practically demanding some sort of medicne for delusional or combative patients. They will even suggest medicines by name. Often, these phone calls occur at 3:00 AM, and the doctor gives a quick yes to give them an answer and get back to sleep....

June 5, 2008
Novartis and Multiple Sclerosis: A Major Commitment
Analysis of: Extavia® approved in E.U for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis | www.asia-manufacturing.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.

Extavia, Novartis' brand of interferon beta 1b, has been approved for the treatment of multiple sclerosis by the European Union. With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009. While essentially identical to Bayer's Betaferon interferon beta 1b,...

June 2, 2008
Abbott's ABT-089 --Much More than a Treatment for ADHD
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.

The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD. The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.

May 28, 2008

obviously works better
Analysis of: New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone | www.novartis.com
Author: GLG Expert Contributor

The info that tekturna HCT works twice as well as HCTZ alone is not earth shattering. Of course it's better. That can be said of any HCT/medicine combination

April 24, 2008
COPAXONE from the START of MS
Analysis of: Teva Seeks Approval for the Extension of its Indication to Include the Treatment of Patients with a First Clinical Event Suggestive of MS | www.pipelinereview.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.

Copaxone has become the leading treatment for relapsing remitting MS in the US. The results of the PRECISE trial will likely add to TEVA's sales momentum and boost sales further.

February 15, 2008
Win for Talecris' Gamunex IVIG in Inflammatory Polyneuropathy
Analysis of: Positive Results from Phase III Trial of Gamunex in Patients with CIDP | pharmalive.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.

Talecris' form of IVIG, Gamunex was studied in the largest trial of IVIG in chronic inflammatory polyradiculoneuropathy (CIDP), with more than twice as many patients moving into remission. CIDP is a common acquired autoimmune peripheral neuropathy, which if not treated, may lead to a peripheral...

February 4, 2008
SILENOR -- A Sleeper among Hypnotics
Analysis of: Somaxon Pharmaceuticals Submits New Drug Application For SILENOR(TM) For The Treatment Of Insomnia | www.pipelinereview.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.

Somaxon Pharmaceuticals has submitted a NDA for Silenor for the treatment of insomnia. The active ingredient is doxepin, which has been available for years.The effect of the drug can be expected to be very modest, side effects unfavorable when compared to Ambien or Lunesta, and with both significant...

January 30, 2008

Geographic Location Key In Walk-In Clinic Locations
Analysis of: Operator of Walk-In Clinics Shuts 23 Located in Wal-Mart Stores | www.nytimes.com
Author: GLG Expert Contributor

It is important to understand that geographic placement of these clinics is important. I think these clinics will continue to pop up until the industry feels out exactly where the market is. We are located in the southwest suburbs of Chicago, and there are many of these clinics which are...

January 18, 2008
Major Win For Glaxo with Xenoport for Restless Legs syndrome -- Next Blockbuster?
Analysis of: GlaxoSmithKline and XenoPort report positive top-line results of second phase 3 restless legs syndrome trial for XP13512/GSK1838262 | www.pipelinereview.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.

Xenoport's trial for XP13512 in restless legs syndrome (RLS) shows strongly positive 9 month data in second phase 3 trial, should be a major win in the marketplace. RLS represent a major unmet need, for drugs with sustained efficacy and high tolerability.

August 30, 2007

Looking forward to Vical Phase 1 Trial of H5N1
Analysis of: Vical Begins Phase 1 Trial Of DNA Vaccine Against H5N1 Pandemic Influenza | www.medicalnewstoday.com
Author: GLG Expert Contributor

I'm looking forward to the results of the H5N1 clincial trial. This might improve the world's chances of avoiding a pandemic like the one in 1918.

Page : 1 2 3 Next1 to 10 of 23

More GLG News in
Healthcare

GLG News: What Experts Think Is Important

Generated at 2008-09-05T09:45:16.717

GLG News by Cymbalta Prescribers for Neuropathic Pain (US)

More GLG News inHealthcare

GLG News: What Experts Think Is Important

More GLG News in
Healthcare